Antiviral therapy of chronic hepatitis C: 30 years success story
- 作者: Abdurakhmanov D1, Rozina T1, Nikulkina E1, Burnevich E1, Tanashuk E1, Severov M1, Filatova A1, Milovanova S1, Karpov V1, Moiseev S1
-
隶属关系:
- Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical University
- 期: 卷 91, 编号 11 (2019)
- 页面: 110-115
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33721
- DOI: https://doi.org/10.26442/00403660.2019.11.000470
- ID: 33721
如何引用文章
全文:
详细
作者简介
D Abdurakhmanov
Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical University
Email: abdjamal@mail.ru
д.м.н., проф. каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава Россииu; ORCID: 0000-0002-3160-2771 Moscow, Russia
T Rozina
Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical Universityк.м.н., доцент каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России Moscow, Russia
E Nikulkina
Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical Universityассистент каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России Moscow, Russia
E Burnevich
Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical Universityк.м.н., доцент каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России Moscow, Russia
E Tanashuk
Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical Universityк.м.н., ассистент каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России Moscow, Russia
M Severov
Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical Universityк.м.н., доцент каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России Moscow, Russia
A Filatova
Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical Universityк.м.н., ассистент каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России Moscow, Russia
S Milovanova
Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical Universityд.м.н., доцент каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России Moscow, Russia
V Karpov
Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical Universityк.м.н., ассистент каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России Moscow, Russia
S Moiseev
Tareev Clinic of Rheumatology Nephrology and Occupational Disease Sechenov First Moscow State Medical Universityд.м.н., проф., зав. каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России Moscow, Russia
参考
- Feinstone S.M, Kapikian A.Z, Purcell R.H, Alter H.J, Holland P.V. Transfusion - associated hepatitis not due to viral hepatitis type A or B. N Engl J Med. 1975;292,767-70. doi: 10.10 56/NEJM197504102921502
- Berman M, Alter H.J, Ishak K.G, Purcell R.H, Jones E.A. The chronic sequelae of non-A, non-B hepatitis. Ann Intern Med. 1979;91:1-6. doi: 10.7326/0003-4819-91-1-1
- Сергиев П.Г., Тареев Е.М., Гонтаева А.А. и др. Вирусная желтуха (эпидемический гепатит в связи с иммунизацией человеческой сывороткой). Терапевтический архив. 1940;17(6):596-611.
- Choo Q.L, Kuo G, Weiner A.J, et al. Isolation of a cDNA clone derived from a blood - borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-62. doi: 10.1126/science.2523562
- Marcellin P. Hepatitis B and hepatitis C in 2009. Liver International. 2009;29(s1):1-8. doi: 10.1111/j.1478-3231.2008.01947.x
- Cooke G, Andrieux-Meyer I, Applegate T, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135-84. doi: 10.1016/S2468-1253(18)30270-X
- Davis G.L, Balart L.A, Schiff E.R, Lindsay K, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Eng J Med. 1989;321(22):1501-06. doi: 10.1056/NEJM198911303212203
- Brillanti S, Garson J, Foli M, Whitby K, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa - resistant chronic hepatitis C. Gastroenterology. 1994; 107(3):812-7. doi: 10.1016/0016-5085(94)90131-7
- Manns M.P, McHutchison J.G, Gordon S.C, Rustgi V.K, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(22):958-65. doi: 10.1016/s0140-6736(01)06102-5
- Fried M.W, Shiffman M.L, Reddy K.R, Smith C, Marinos G, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-82. doi: 10.1056/NEJMoa020047
- Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, et al. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology. 2017;152(1):142-56. doi: 10.1053/j.gastro
- Simmons B, Saleem J, Heath K, et al. Long - term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta - analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61:730-40. doi: 10.1093/cid/civ396
- Poordad F, Mc Cone J, Bacon B.R, Bruno S, et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection. N Engl J Med. 2011;364:1195-206. doi: 10.1056/NEJMoa1010494
- Jacobson I.M, Mc Hutchison J.G, Dusheiko G, Di Bisceglie A.M, et al. N Engl J Med. 2011;364:2405-16. doi: 10.1056/NEJMoa1012912
- Colombo M, Fernández I, Abdurakhmanov D, Ferreira Р.А, et al. Safety and on - treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut. 2014;63:1150-8. doi: 10.1136/gutjnl-2013-305667
- Jacobson I, Zeuzem S, Flisiak R, Knysz B, et al. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World J Gastroenterol. 2016;22(12):3418-31. doi: 10.3748/wjg.v22.i12.3418
- Lawitz E, Sulkowski M.S, Ghalib R, Rodriguez-Torres M, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non - responders to pegylated interferon and ribavirin and treatment - naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756-65. doi: 10.1016/S0140-6736(14)61036-9
- Manns M, Pol S, Jacobson I.M, Marcellin P, et al. All - oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014; 384(9954):1597-605. doi: 10.1016/S0140-6736(14)61059-X
- Feld J.J, Kowdley K.V, Coakley E, Sigal S, et al. Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med. 2014;370:1594-603. doi: 10.1056/NEJMoa13157 22
- Sulkowski M.S, Gardiner D.F, Rodriguez-Torres M, Reddy K.R, et al. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. N Engl J Med. 2014;370:211-21. doi: 10.1056/NEJMoa1306218
- Isakov V, Chulanov V, Abdurakhmanov D, Burnevich E, et al. Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open - label study in Russia and Sweden. Infect Dis (Lond). 2019;51(2):131-9. doi: 10.1080/23744235.2018.1535186
- Jacobson I.M, Lawitz E, Gane E.J, Willems B.E, et al. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology. 2017;153(1):113-22. doi: 10.1053/j.gastro.2017.03.047
- Zeuzem S, Foster G.R, Wang S, Asatryan A, et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018;378(4):354-69. doi: 10.1056/NEJ Moa1702417
- Bourlière M, Gordon S.C, Flamm S.L, Cooper C.L, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017;376:2134-46. doi: 10.1056/NEJMoa1613512
- Poordad F, Felizarta F, Asatryan A, Sulkowski M.S, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct - acting antiviral treatment. Hepatology. 2017;66(2):389-97. doi: 10.1002/hep.29081
- Abdurakhmanov D.T, Rozina T.P, Nikulkina E.N, Nabatchikova E.A, Chulanov V.P, Moiseev S.V. Sofosbuvir - based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance. Antivir Ther. 2018;23(8):705-8. doi: 10.3851/IMP3266
- Artemova M, Abdurakhmanov D, Ignatova T, Mukhin N. Persistent Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Following Virus Eradication After Direct-Acting Antiviral Therapy. Hepatology. 2017;65(5):1770-71. doi: 10.1002/hep.28981
- Zubkin M.L, Abdurakhmanov D.T, Sagalova O.I, Bakulin I.G, Maevskaya M.V, Ivashkin V.T. Persistent mixed cryoglobulinemia after successful antiviral treatment of chronic hepatitis C virus infection: What's the next? Scandinavian J Gastroenterology. 2018;53(7):883-4. doi: 10. 1080/00365521.2018.1477988
- Gragnani L, Visentini M, Fognani E, Urraro T, et al. Prospective study of guideline - tailored therapy with direct - acting antivirals for hepatitis C virus - associated mixed cryoglobulinemia. Hepatology. 2016;64:1473-82. doi: 10.1002/hep.28753
- Calvaruso V, Cabibbo G, Cacciola I, Petta S, et al. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2018;155(2):411-21. doi: 10.1053/j.gastro.2018.04.008
- Lleo A, Aglitti A, Aghemo A, Maisonneuve P, et al. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Dig Liver Dis. 2019;51(2):310-17. doi: 10.1016/j.dld.2018.10.014
- Ioannou G.N, Green P.K, Berry K. HCV eradication induced by direct - acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2018;68:25-32. doi.org: 10.1016/j.jhep.2017.08.030
- Höner Zu Siederdissen C, Maasoumy B, Marra F, Deterding K, et al. Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. Clin Infect Dis. 2016;62(5):561-7. doi: 10.1093/cid/civ973
- Hudson B, Walker A.J, Irving W.L. Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK. J Med Virol. 2017;89(12):2158-64. doi: 10.1002/jmv.24848